Cargando…
Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor on T-cells and blocks its interaction with PD-L1 and PD-L2, releasing the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor...
Autores principales: | Zahoor, Fatima, Ahmed, Najia, Afzal, Ghazal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381033/ https://www.ncbi.nlm.nih.gov/pubmed/35989738 http://dx.doi.org/10.7759/cureus.26950 |
Ejemplares similares
-
Linezolid and Ciprofloxacin-Induced SJS/TEN (Stevens-Johnson Syndrome/Toxic Epidermolysis Necrosis) Overlap in a Patient With Borderline Personality Disorder During a Single Hospital Stay: A Difficult Case to Manage
por: Memon, Shafia, et al.
Publicado: (2023) -
Dermoscopic Nail Disorders in School-Going Children
por: Zahoor, Fatima, et al.
Publicado: (2023) -
Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017) -
Current clinico-mycological trends of onychopathies in Casablanca
por: Badaoui, L, et al.
Publicado: (2014) -
Photosensitive rash induced by nivolumab()
por: Navarro-Triviño, Francisco J., et al.
Publicado: (2022)